Factors associated with withholding of invasive mechanical ventilation in the early phase of the COVID-19 response and their ethical analyses.

Publication date: Jun 30, 2025

End-of-life decision making regarding invasive mechanical ventilation (IMV) for patients with severe coronavirus disease (COVID-19) is challenging. We aimed to explore the factors associated with the withholding of IMV in patients with COVID-19. This retrospective study included patients registered in a nationwide COVID-19 Registry Japan. We enrolled patients with COVID-19 admitted between January 1, 2020, and June 30, 2021, and died during hospitalization. The enrolled patients were divided into two groups: those who received IMV (IMV group) and those who did not (non-IMV group). To identify the factors associated with withholding of IMV among patients with COVID-19 who died during hospitalization, we conducted a multivariate logistic regression analysis. A total of 2,401 patients were enrolled. Of these, 588 (24. 5%) were in the IMV group and 1813 (75. 5%) in the non-IMV group. Withholding IMV was positively associated with older age (95% confidence interval [CI]: 0. 82-0. 88, p < 0. 0001), dementia (95% CI: 0. 81-0. 91, p < 0. 0001), chronic lung disease (95% CI: 0. 88-1. 00, p = 0. 036), and malignancy (95% CI: 0. 82-0. 94, p < 0. 0004) although inversely associated with male sex (95% CI: 1. 04-1. 15, p = 0. 0008), body mass index (95% CI: 1. 01-1. 02, p < 0. 0001), and National Early Warning Score (95% CI: 1. 01-1. 03, p < 0. 0001). We subsequently analyzed these results to inform preparedness for future emerging infectious disease pandemics by retrospectively examining the decision-making processes during the COVID-19 crisis, with particular attention to the role of multidisciplinary collaboration. Based on this study, it will be essential in future pandemics to assess decisions concerning life-sustaining treatments, including IMV, from both scientific and ethical perspectives.

Open Access PDF

Concepts Keywords
Coronavirus decision-making
Dementia end-of-life
June severe COVID-19

Semantics

Type Source Name
disease MESH COVID-19
disease MESH End-of-life
pathway KEGG Coronavirus disease
disease MESH dementia
disease MESH lung disease
disease MESH malignancy
disease MESH emerging infectious disease
disease IDO role
disease MESH respiratory failure
drug DRUGBANK Etoperidone
disease MESH infection
disease IDO process
disease IDO facility
disease IDO history
drug DRUGBANK Oxygen
disease IDO blood
disease MESH emergency
disease IDO symptom
disease MESH comorbidity
drug DRUGBANK Coenzyme M
drug DRUGBANK Ethanol
disease MESH Myocardial infarction
disease MESH Congestive heart failure
disease MESH Paralysis
disease MESH COPD
disease MESH Hypertension
disease MESH Diabetes Mellitus
disease MESH AIDS
disease MESH chronic kidney disease
disease IDO immunodeficiency
disease MESH critically ill
disease MESH obesity
disease MESH frailty
disease MESH complications
drug DRUGBANK Isoxaflutole
drug DRUGBANK Methionine
disease MESH pneumonia
disease MESH Infectious Disease
pathway REACTOME Infectious disease
pathway REACTOME Release
disease MESH out of hospital cardiac arrest
disease MESH Emotional stress
disease MESH coronavirus infection
disease MESH fatal outcome

Original Article

(Visited 5 times, 1 visits today)